4-Methyl-α-methyltryptamine
4-Me-αMT, or 4-Me-AMT, also known as 4-methyl-α-methyltryptamine or as 4,α-dimethyltryptamine, is an experimental antidepressant of the tryptamine and α-alkyltryptamine families that was never marketed. It is closely structurally related to serotonergic psychedelics and entactogens like α-methyltryptamine and α-ethyltryptamine.4-Me-αMT is active at a dose of 20 to 60mg orally in humans, though described as being an antidepressant rather than a hallucinogen. It was found to be effective as an antidepressant in preliminary clinical studies. Alexander Shulgin has said that 4-Me-αMT produced some feelings of unreality at 20mg, as well as skin flushing, muscle tightness, and mydriasis. However, he has said that it could not be called a hallucinogen at assessed doses and has listed the hallucinogenic dose as being greater than 60mg.Interactions
Pharmacology
Pharmacodynamics
4-Me-αMT partially reverses reserpine-induced behavioral depression in rodents, but does not produce hyperlocomotion. This was the case at a dose of 50mg/kg, whereas αMT produced clear hyperlocomotion and near-fully reversed reserpine-induced hypoactivity at a dose of 15mg/kg. Hence, 4-Me-αMT shows reduced antidepressant- and psychostimulant-like potency compared to αMT. It is also less active than αET. The drug is said to have very weak monoamine oxidase inhibition.Chemistry
Analogues
s of 4-methyl-AMT include α-methyltryptamine, 4-methyl-AET, 4-methyl-DMT, 4-HO-AMT, 4-HO-AET, and RS134-49, among others.History
4-Me-αMT was first described in the scientific literature by 1962. It was investigated as an antidepressant by Sandoz in Canada in the early 1960s, although it was never marketed.